RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat
, will host a hybrid Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York. The event will feature presentations from Marinus management and Key Opinion Leaders to discuss the Company’s clinical pipeline progress, strategic initiatives and business outlook.
In-person attendance is open to invited research analysts and institutional investors. All others are invited to watch the live video webcast. Live questions will be taken by in-person guests, and virtual participants may submit questions through the webcast platform.
To register for the video webcast, please visit the Investor Relations section of the Company's website at . A replay of the webcast will be archived on the Investor Relations section of the Company's website following the event.
About Marinus PharmaceuticalsMarinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for
. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of
CDKL5 deficiency disorder
deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare